Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

Latest Posts

Pherecydes Pharma granted a new patent for its anti-Pseudomonas aeruginosa phages in Europe

22 March 2022

Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the... View Article

OSE Immunotherapeutics provides positive long term memory responses with CoVepiT, its T lymphocyte multi-target anti-COVID vaccine

17 March 2022

Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.... View Article

SEABELIFE RECEIVES CLOSE TO €1.4M DEEP TECH FINANCING FROM BPIFRANCE

14 March 2022

Funds will enable SeaBeLife to develop pipeline of innovative molecules intended to block programmed cell death in cases of acute... View Article

« Previous 1 … 23 24 25 26 27 … 160 Next »